TITLE

saquinavir:

AUTHOR(S)
Huber, Jeffrey T.; Gillaspy, Mary L.
PUB. DATE
October 2000
SOURCE
Encyclopedic Dictionary of AIDS-Related Terminology;2000, p195
SOURCE TYPE
Book
DOC. TYPE
Reference Entry
ABSTRACT
An encyclopedia entry for saquinavir is presented. Saquinavir is the first protease inhibitor approved by the U.S. Food and Drug Administration. The drug was approved more quickly than any other new HIV drug at that time. Saquinavir is manufactured by Roche Laboratories, with the trade name Invirase.
ACCESSION #
23076556

 

Related Articles

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • New & improved.  // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p108 

    Reports that the US Food and Drug Administration has granted marketing clearance for Hoffman-La Roche's Fortovase (saquinavir), a soft gelatin formulation of the first available protease inhibitor. Indication of the drug.

  • Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? Nolan, David // Drug Safety;2005, Vol. 28 Issue 12, p1069 

    Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over the past 6 years has now clarified the...

  • Roche files saquinavir NDA.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.

  • Improved formulation of AIDS drug granted approval.  // Drug Store News;12/8/97, Vol. 19 Issue 20, pCP4 

    Reports the marketing approval granted to Hoffmann-LaRoche Inc. for the improved soft gelatin formulation of its protease inhibitor Invirase (saquinavir mesylate). Features of the product and its effectivity; Availability of Invirase.

  • A lifesaving cocktail. Romesburg, Don // Advocate;1/17/2006, Issue 954, p8 

    The article recalls the introduction of protease inhibitors in December 1995. With the introduction of saquinavir and two other anti-HIV drugs, patients were seeing HIV viral loads drop to undetectable levels and they were reengaging with the future. The drugs were expensive and had side effects...

  • Cocktail all in one. Kuhr, Fred // Advocate;1/17/2006, Issue 954, p44 

    The article addresses the problems associated with the use of the active antiretroviral therapy to treat HIV. By mid-1990s two new classes of anti-HIV drugs were introduced, one with protease inhibitors was introduced in December 1995 and other one with nonnucleoside reverse transcriptase...

  • Can the thymus win the battle against drug-resistant HIV? Haynes, Barton F.; Sempowski, Gregory D. // Nature Medicine;Jun2001, Vol. 7 Issue 6, p661 

    Focuses on the replication of protease inhibitors (PI) resistant HIV in the human thymus. Causes of PI resistance in the HIV protease gene; Effect of differences in signaling and cytokine production on the ability of PI-resistant HIV to replicate in thymocytes.

  • Fosamprenavir. Ellis, Jennifer M.; Ross, Jack W.; Coleman, Craig I. // Formulary;Mar2004, Vol. 39 Issue 3, p151 

    Fosamprenavir ( Lexiva, GlaxosSmithKline/Vertex) is the latest protease inhibitor (PI) approved by FDA for the treatment HIV-1 infection. A prodrug of amprenavir (APV), fosamprenavir has improved solubility and bioavailability over the parent PI, allowing for once-or twice-daily dosing and a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics